Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2006 | View Paper
“Sequential treatment with paricalcitol (12.5, 25, or 50 nM) followed by docetaxel (50, 100, or 200 nM) produced synergistic growth inhibition for all dose combinations in both cell lines.”